4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. is trading at $14.67, up 0.86% on the session. The 50 day average sits at $10.86 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 64.1, which reads as strong, and MACD is bullish crossover. Volume is above average.

The nearest support is around $10.29 with resistance near $14.00, so that band frames the current range. Average daily movement is roughly $0.71, or about 4.9% of the share price, which is what any stop placement has to allow for. The overall health score of 63 out of 100 combines a trend score of 59, momentum of 86 and a risk score of 38.

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.